Skip to main content
Uncategorized

Tom Hudson, coordinator of the International Cancer Genome Consortium, visits the CNAG

By 13 de October de 2010November 18th, 2020No Comments
< Back to news
 13.10.2010

Tom Hudson, coordinator of the International Cancer Genome Consortium, visits the CNAG

Tom Hudson, coordinator of the International Cancer Genome Consortium (ICGC) and president and scientific director of the Ontario Institute for Cancer Research, today has visited the National Center for Genomics Analysis (CNAG), which is hosted by the Barcelona Science Park, in order to participate in a work meeting with the Spanish team that is working on this project. The objective of the ICGC is to obtain a comprehensive description of genomic, transcriptomic and epigenomic alterations or anomalies present in 50 types and subtypes of different tumors in order to foster the advance of research aimed at improving the detection and treatment of these pathologies.


In addition to Spain, eight other countries that are leaders in human genome research are participating in this project: the United States, Canada, Australia, Japan, China, India, France and the United Kingdom. Spanish researchers have the mission of deciphering the genome of chronic lymphocytic leukemia (CLL), one of the most frequent tumors in the Western world.

During his visit to the CNAG, Hudson was accompanied by Peter Klatt, advisor to the State Secretary for Research and member of the Executive Committee of the ICGC; Elías Campo, clinical director of the Center for Biomedical Diagnosis (CDB) of the Clinical Hospital of Barcelona and scientific coordinator of the Spanish contribution to the ICGC, and the director of the CNAG, Ivo Gut, one of the most renowned scientists in Europe in this field.

The mission of the National Center for Genomic Analysis is to ensure the successful participation of Spain in this consortium, by developing and applying the latest technology for the massive sequencing of tumour samples, covering the growing demand for sequencing in relation to large scale genomic research projects and guaranteeing the competitiveness of Spain in this strategic field.